CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Valneva SE is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Valneva SE
6 rue Alain Bombard
Phone: +33 228073710p:+33 228073710 SAINT-HERBLAIN, 44800  France Ticker: VLAVLA
Business Summary
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Anne-MarieGraffin 63 12/20/2023 3/7/2013
President, Chief Executive Officer, Director ThomasLingelbach 60 12/20/2023 1/1/2012
Independent Vice Chairman of the Board James R.Sulat 73 1/1/2024 3/7/2013
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Intercell AG Campus Vienna Biocenter 3 Wien Austria
Valneva USA, Inc. 910 Clopper Road Gaithersburg MD United States
Iomai Corporation 910 Clopper Road, Suite 160S GAITHERSBURG MD United States

Business Names
Business Name
0OB3
0QS6
BLiNK Biomedical SAS
21 additional Business Names available in full report.

General Information
Number of Employees: 695 (As of 6/30/2024)
Outstanding Shares: 139,152,579 (As of 9/30/2024)
Shareholders: 78
Stock Exchange: EPA
Fax Number: +33 144217078


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024